Literature DB >> 9719026

Differential transactivation by the androgen receptor in prostate cancer cells.

R Snoek1, N Bruchovsky, S Kasper, R J Matusik, M Gleave, N Sato, N R Mawji, P S Rennie.   

Abstract

BACKGROUND: The purpose of this study was to determine the contribution of different transactivating regions of the androgen receptor (AR) to the induction of androgen-regulated promoters in poorly (PC3 cells) and well-differentiated (LNCaP cells) prostate cancer cell lines.
METHODS: PC3 and LNCaP cells were co-transfected with plasmids expressing full-length AR or deletion mutants together with luciferase reporters linked to the probasin (PB) and PSA promoters; as well as to ARR3tk, a PB-derived recombinant promoter.
RESULTS: Androgen induction of the ARR3tk promoter in the presence of AR was 8- to 10-fold higher than that seen with the PB promoter. Activation of ARR3tk was greatest with an androgen-independent construct in which the first 231 amino acids and the ligand binding domain had been removed, indicating that this promoter is more responsive to activating functions in the N-terminal domain than in the ligand binding domain. By comparison, induction of the PB promoter was greatest with the full-length AR, which suggests that the ligand binding domain also makes a major contribution to the activation of this promoter. In similar analyses with the PSA promoter, AR regions required for promoter induction was dependent on the host cell type. In PC3 cells, the predominant AR transactivation function was androgen-independent and resided in the N-terminal domain, whereas in LNCaP cells, the highest level of induction was androgen dependent and also required participation of the ligand binding domain.
CONCLUSIONS: Our results indicate that the relative utilization of transactivating functions in N-terminal and ligand binding domains of the AR is promoter and cell specific.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719026     DOI: 10.1002/(sici)1097-0045(19980901)36:4<256::aid-pros7>3.0.co;2-d

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.

Authors:  J Woraratanadharm; S Rubinchik; H Yu; F Fan; S M Morrow; J Y Dong
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

2.  Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

Authors:  Nathan A Lack; Peter Axerio-Cilies; Peyman Tavassoli; Frank Q Han; Ka Hong Chan; Clementine Feau; Eric LeBlanc; Emma Tomlinson Guns; R Kiplin Guy; Paul S Rennie; Artem Cherkasov
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

Review 3.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

4.  Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Authors:  Kush Dalal; Mani Roshan-Moniri; Aishwariya Sharma; Huifang Li; Fuqiang Ban; Mohamed Hessein; Michael Hsing; Kriti Singh; Eric LeBlanc; Scott Dehm; Emma S Tomlinson Guns; Artem Cherkasov; Paul S Rennie
Journal:  J Biol Chem       Date:  2014-08-01       Impact factor: 5.157

5.  Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.

Authors:  Y Yang; A K-W Tse; P Li; Q Ma; S Xiang; S V Nicosia; E Seto; X Zhang; W Bai
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

6.  Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.

Authors:  Mariia Radaeva; Huifang Li; Eric LeBlanc; Kush Dalal; Fuqiang Ban; Fabrice Ciesielski; Bonny Chow; Helene Morin; Shannon Awrey; Kriti Singh; Paul S Rennie; Nada Lallous; Artem Cherkasov
Journal:  Cells       Date:  2022-09-07       Impact factor: 7.666

7.  Stat3 enhances transactivation of steroid hormone receptors.

Authors:  Fernando De Miguel; Soo Ok Lee; Sergio A Onate; Allen C Gao
Journal:  Nucl Recept       Date:  2003-06-13

8.  GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance.

Authors:  Eugine Lee; John Wongvipat; Danielle Choi; Ping Wang; Young Sun Lee; Deyou Zheng; Philip A Watson; Anuradha Gopalan; Charles L Sawyers
Journal:  Elife       Date:  2019-01-15       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.